FABP

Artelo Biosciences Announces Publication of Peer-Reviewed Article Highlighting FABP7 as a Promising Novel Target in Cancer Therapy

Retrieved on: 
화요일, 4월 23, 2024
Pain, FDA, Brain, Cancer, Food, Prognosis, Survival, Breast, Research, FABP5, Transport, Dicarboxylic acid, IND, Drug discovery, Patient, Metabolism, Neuropathic pain, FABP, FABP7, Chemotherapy-induced peripheral neuropathy, Pharmaceutical industry

Additionally, the evidence shows that both genetic and pharmacological inhibition of FABP7 led to reduced tumor cell growth, migration, and invasion in multiple studies.

Key Points: 
  • Additionally, the evidence shows that both genetic and pharmacological inhibition of FABP7 led to reduced tumor cell growth, migration, and invasion in multiple studies.
  • Moreover, inhibition of FABP7 improved host survival rates, particularly in brain cancers, indicating its role as a novel target in cancer.
  • In preclinical studies, ART26.12 demonstrated positive results in cancer, cancer bone pain, and painful neuropathies such as chemotherapy-induced peripheral neuropathy (CIPN).
  • For more information about Artelo Biosciences and our commitment to innovative therapies, please visit our website at www.artelobio.com

Artelo Biosciences Selected as a Finalist in Johnson & Johnson’s Innovation Challenge

Retrieved on: 
화요일, 3월 12, 2024
Dermatology, Atopic dermatitis, Inflammation, JNJ, Research, American Academy, Cancer, FABP5, Skin, FABP, Pain, Epidermis, Oxidative stress, Pharmaceutical industry

SOLANA BEACH, Calif., March 12, 2024 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. (Nasdaq: ARTL), a clinical-stage pharmaceutical company focused on modulating lipid-signaling pathways to develop treatments for people living with cancer, pain, and neurological conditions, today announced its selection as a finalist in Johnson & Johnson’s (“J&J’s”; NYSE: JNJ) Innovation Challenge .

Key Points: 
  • SOLANA BEACH, Calif., March 12, 2024 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. (Nasdaq: ARTL), a clinical-stage pharmaceutical company focused on modulating lipid-signaling pathways to develop treatments for people living with cancer, pain, and neurological conditions, today announced its selection as a finalist in Johnson & Johnson’s (“J&J’s”; NYSE: JNJ) Innovation Challenge .
  • Artelo was awarded the opportunity to present preclinical dermatology research on ART26.12 in San Diego, California, on March 11, 2024, concurrent with the American Academy of Dermatology Annual Meeting.
  • "We are pleased to have been selected to present our ART26.12 program to the J&J immuno-dermatology leadership team," said Dr. Andrew Yates, Chief Scientific Officer of Artelo.
  • “Our drug discovery program is investigating several oral, small molecule, FABP5 inhibitors,” said Professor Saoirse O'Sullivan, Vice President Translational Science of Artelo.

Artelo Biosciences to Present New Mechanism of Action Data on ART26.12 at the Gordon Research Conference on July 20, 2023

Retrieved on: 
수요일, 7월 19, 2023
Gordon Research Conferences, Diabetic neuropathy, Cancer, National Center for Advancing Translational Sciences, Doctor of Philosophy, Transcriptome, Pain, Gordon, Food and Drug Administration Amendments Act of 2007, FABP, Therapy, IND, Conference, Food, Pharmaceutical industry

https://www.grc.org/cannabinoid-function-in-the-cns-conference/2023/

Key Points: 
  • https://www.grc.org/cannabinoid-function-in-the-cns-conference/2023/
    “I am looking forward to sharing our data on the potential applications of inhibiting fatty acid binding proteins from our extensive library of compounds,” said Professor O’Sullivan.
  • “We are particularly excited to share new information on the effects of our FABP inhibitor ART26.12 on not only cannabinoid receptors, but other receptors implicated in pain signaling, as well as lipidomic and transcriptome data that help us understand how ART26.12 elicits its effects in peripheral neuropathies.”
    Professor O’Sullivan’s presentation on Thursday, July 20, 2023 includes data on ART26.12, Artelo’s lead compound targeting a variety of painful neuropathies, as well as the potential of FABP inhibitors beyond peripheral neuropathies.
  • ART26.12 was selected from Artelo’s platform of inhibitors to FABPs as its first candidate drug.
  • The Company recently announced it expects pre-IND meeting feedback on its IND planning and development strategy from the Food and Drug Administration during the third quarter of this year with the goal of initiating clinical development in early 2024.

Artelo Biosciences Reports Fiscal 2022 Year-End Financial Results and Provides Business Update

Retrieved on: 
금요일, 3월 31, 2023
Cortex, Patent, Trinity College, University, FABP5, CB2, Neoplasm, Anxiety, Cerebral cortex, Oxaliplatin, Diabetic neuropathy, Weight loss, National Center for Advancing Translational Sciences, Cancer, Toxicity, Brain, Research, ICRS, Pain, Biochemistry, Trinity College Dublin, Cachexia, Patient, International Cannabinoid Research Society, School, FABP, Cannabidiol, Pharmaceutical industry, Cryptocurrency, CBD

SOLANA BEACH, Calif., March 31, 2023 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. (Nasdaq:ARTL), a clinical-stage pharmaceutical company focused on modulating lipid-signaling pathways to develop treatments for people living with cancer, pain, and neurological conditions, today reported financial and operating results for the fiscal year ended December 31, 2022 and provided a business update.

Key Points: 
  • SOLANA BEACH, Calif., March 31, 2023 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. (Nasdaq:ARTL), a clinical-stage pharmaceutical company focused on modulating lipid-signaling pathways to develop treatments for people living with cancer, pain, and neurological conditions, today reported financial and operating results for the fiscal year ended December 31, 2022 and provided a business update.
  • “We achieved meaningful clinical progress throughout 2022,” stated Gregory D. Gorgas, President and Chief Executive Officer of Artelo Biosciences.
  • Given ART27.13’s better-than-expected safety profile and absence of drug-related grade three or four toxicity, we elected to advance to a fourth cohort at a 650-microgram dose.
  • Fiscal 2022 Year-End Financial Results:
    Operating expenses for the year ended December 31, 2022 were $10.3 million compared to $4.0 million for the four months ended December 31, 2021, and $7.4 million for the year ended August 31, 2021.

Artelo Biosciences Reports Third Quarter 2022 Financial Results and Provides Business Update

Retrieved on: 
화요일, 11월 8, 2022
PTSD, FABP, Research, Neuroscience, Securities Exchange Act of 1934, Company, Security (finance), Drug Quality and Security Act, Industry, AstraZeneca, Pain, Weight gain, Organic acid, Anxiety, Securities Act of 1933, U.S. Securities and Exchange Commission, Weight loss, Inflammation, Cancer, Anorexia nervosa, Patient, Drug discovery, Investigational New Drug, Protein, Radiation, Doctor of Philosophy, Nasdaq, Peripheral neuropathy, CB2, CB1, Achievement, University, Toxicity, Dehydration, Society, FDA, GLOBE, Purging disorder, Investment, Nature, Appetite, Lipid, Private Securities Litigation Reform Act, Cannabinoid, Immune system, FABP5, International Cannabinoid Research Society, Human, Pharmaceutical industry, Renewable energy

SOLANA BEACH, Calif., Nov. 08, 2022 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. (Nasdaq: ARTL), a clinical-stage pharmaceutical company focused on modulating lipid-signaling pathways to develop treatments for people living with cancer, pain, and neurological conditions, today reported financial and operating results for the three months ended September 30, 2022 and provided a business update.

Key Points: 
  • Once clinical results are evaluated, we expect to commence enrollment of our Phase 2a clinical trial near year-end, stated Gregory D. Gorgas, President and Chief Executive Officer of Artelo Biosciences.
  • With regulatory enabling research well underway, Artelo anticipates filing an Investigational New Drug application with the FDA late next year.
  • Financial Results Ended September 30, 2022
    Operating expenses for the three months ended September 30, 2022, were $2.4 million compared to $2.2 million for the same period in 2021.
  • Artelo Biosciences, Inc. is a clinical-stage pharmaceutical company focused on modulating lipid-signaling pathways to develop treatments for people living with cancer, pain, and neurological conditions.

Artelo Biosciences Reports Positive Pre-Clinical Results with its Novel Inhibitor to Fatty Acid Binding Protein 5

Retrieved on: 
화요일, 8월 16, 2022
Cortex, U.S. Securities and Exchange Commission, Securities Act of 1933, University, Cerebral cortex, Inflammation, Industry, Stony Brook University, GLOBE, Peripheral neuropathy, Cancer, Brain, Fear, Securities Exchange Act of 1934, Purging disorder, Security (finance), Research, Pain, Post-traumatic stress disorder, FABP5, Doctor of Philosophy, Lipid, Twitter, Cannabinoid, CB2, Anxiety, Nature, Neuroscience, Lead, FABP, Protein, Private Securities Litigation Reform Act, Screen for child anxiety related disorders, Diathesis–stress model, Nasdaq, PTSD, Organic acid, Pharmaceutical industry

President and Chief Executive Officer of Artelo Biosciences.

Key Points: 
  • President and Chief Executive Officer of Artelo Biosciences.
  • This new data further supports the development of our FABP inhibitor platform in anxiety-related disorders such as post-traumatic stress disorder.
  • We are encouraged by these findings which indicate inhibiting FABPs represents a promising neurobiological approach for the development of novel anxiety-inhibiting pharmacotherapies.
  • Artelo Biosciences, Inc. is a clinical-stage pharmaceutical company focused on modulating lipid-signaling pathways to develop treatments for people living with cancer, pain, and neurological conditions.

Artelo Biosciences Reports Second Quarter 2022 Financial Results and Provides Business Update

Retrieved on: 
화요일, 8월 9, 2022
U.S. Securities and Exchange Commission, GLOBE, Cancer, Investment, Toxicity, Board, Purging disorder, AstraZeneca, Security (finance), Pain, Peripheral neuropathy, Patient, Appetite, Securities Act of 1933, Securities Exchange Act of 1934, Immune system, Inflammation, Industry, FABP5, Lipid, Cannabinoid, Șaeș, CB2, Nature, Board of directors, CB1, Nasdaq, Weight loss, Pharmacokinetics, Anorexia nervosa, Human, Compliance, 8-K, Radiation, Dehydration, Reverse stock split, Anxiety, FABP, Organic acid, RATS, Review, Oxaliplatin, Company, Twitter, Weight gain, Therapy, Protein, Private Securities Litigation Reform Act, Online gambling, Pharmaceutical industry

SOLANA BEACH, Calif., Aug. 09, 2022 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. (Nasdaq: ARTL), a clinical stage pharmaceutical company developing therapeutics that modulate lipid-signaling pathways, including the endocannabinoid system, today reported financial and operating results for the three months ended June 30, 2022.

Key Points: 
  • The Companys common shares will begin trading on a split-adjusted basis on the Nasdaq Capital Market commencing at the market open, August 10, 2022.
  • For further details, all shareholders are invited to review the 8-K regarding this reverse split filed today, August 9, 2022.
  • Financial Results Ended June 30, 2022
    Operating expenses for the three months ended June 30, 2022, were $2.4 million compared to $2.3 million for the same period in 2021.
  • Artelo Biosciences, Inc.is a clinical stage pharmaceutical company dedicated to the development and commercialization of proprietary therapeutics that modulate lipid-signaling pathways including the endocannabinoid system.

Artelo Biosciences Presents Positive Pre-Clinical Results of ART26.12, a Novel FABP5 Inhibitor, in Alleviating Chemotherapy-Induced Pain

Retrieved on: 
월요일, 6월 27, 2022
FDA, Patient, Anxiety, Cannabinoid, Protein, National University of Ireland, Securities Act of 1933, Research, Securities Exchange Act of 1934, ICRS, Peripheral neuropathy, GLOBE, International Cannabinoid Research Society, Â, Cancer, Company, Industry, U.S. Securities and Exchange Commission, Lipid, Pain, FABP, Organic acid, Inflammation, Oxaliplatin, Therapy, Purging disorder, Drug Quality and Security Act, Cannabis, Clinical and Translational Science, Nasdaq, Private Securities Litigation Reform Act, Analgesic, Twitter, FABP5, Nature, Interest, National university, Security (finance), Pharmaceutical industry, CIPN

These results support further development of ART26.12 in neuropathy associated with chemotherapy and other neuropathies, continued Professor OSullivan.

Key Points: 
  • These results support further development of ART26.12 in neuropathy associated with chemotherapy and other neuropathies, continued Professor OSullivan.
  • Development of therapeutics for CIPN represents an attractive, new opportunity for Artelos FABP5 inhibitors, said Gregory D. Gorgas, President and Chief Executive Officer of Artelo Biosciences.
  • Various inhibitors of FABPs may be particularly useful for the treatment of specific cancers, neuropathic and nociceptive pain, and anxiety disorders.
  • Artelo Biosciences, Inc.is a clinical stage pharmaceutical company dedicated to the development and commercialization of proprietary therapeutics that modulate lipid-signaling pathways including the endocannabinoid system.

Artelo Expands Collaboration with Trinity College Dublin to Investigate Cellular Biology of Fatty Acid Binding Protein (FABP) Inhibition In Cancer

Retrieved on: 
월요일, 3월 28, 2022
Company, Cancer, Metabolism, Lipid, Purging disorder, Biochemistry, Post-traumatic stress disorder, Pain, PTSD, Cannabinoid, Research, School, Trinity College Dublin, Organic acid, Anxiety, U.S. Securities and Exchange Commission, Neoplasm, Private Securities Litigation Reform Act, Industry, Securities Exchange Act of 1934, Twitter, Inflammation, Securities Act of 1933, Prostate cancer, Nasdaq, FABP, GLOBE, Drug Quality and Security Act, Nature, Trinity College, Breast cancer, Security (finance), Pharmaceutical industry

Professor Porters focus will be on investigating the molecular basis of fatty acid binding protein (FABP) inhibition in cancer and the potential of the ART26.12 platform for the treatment of various tumors.

Key Points: 
  • Professor Porters focus will be on investigating the molecular basis of fatty acid binding protein (FABP) inhibition in cancer and the potential of the ART26.12 platform for the treatment of various tumors.
  • The potential role and implications of FABP inhibition in different forms of cancer is emerging as a very exciting and promising advancement in cancer research, said Professor Porter.
  • This collaboration with Artelo will further elucidate the specific mechanisms by which targeted FABP inhibition may prevent tumor growth and halt its spreading.
  • FABP plays an important role in lipid signaling and is believed to be an attractive target for cancer drug development.

The Sigourney Award-2021 Honors Three Recipients With Distinguished International Prize for Advancing Psychoanalytic Thought

Retrieved on: 
목요일, 11월 18, 2021
FABP, Research, Patient, Social isolation, Heart, Skin, IPI, Adoption, Mental health, Erikson Institute, School, Neuroscience, Technology, Book, Feminism, Personality, Awareness, Psychoanalysis, MBA, Creativity, Education, Scharff, Psychotherapy, Translation, International Institute of Depth Psychology, City, Medicine, Family, Dermatology, MRC, View, Sigourney, The arts, Associate, Learning, University of Buenos Aires, Multimedia, Suicide, Doctor of Philosophy, Pharmaceutical industry

SEATTLE, Nov. 18, 2021 /PRNewswire/ -- The Sigourney Award annually rewards achievements that advance psychoanalytic thought and practice with international recognition and a substantial cash prize. This year, a panel of distinguished judges evaluated applications from five continents for The Sigourney Award-2021. The work recognized represents significant advancement of psychoanalytic thought. Today, William A. Myerson, Ph.D., MBA, and psychoanalyst co-trustee of The Sigourney Trust, announces three winners whose work merits the prestigious, independent award.

Key Points: 
  • SEATTLE, Nov. 18, 2021 /PRNewswire/ --The Sigourney Award annually rewards achievements that advance psychoanalytic thought and practice with international recognition and a substantial cash prize.
  • This year, a panel of distinguished judges evaluated applications from five continents for The Sigourney Award-2021.
  • Mary Sigourney founded The Sigourney Trust in 1989 to recognize and promote exceptional work that employs psychoanalytic thought to better humankind.
  • The Sigourney Trust, an independent nonprofit organization established by Mary Sigourney in 1989, annually bestows The Sigourney Award as international recognition and reward for outstanding work that employs psychoanalysis and psychoanalytic thought to benefit humankind.